Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of cancer survivors with cancer related cognitive impairment.

Trial Details

NCT ID
NCT06580002
Phase
PHASE2
Sponsor
University of California, Irvine
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Riluzole
  • Placebo
Locations (sample)
  • Orange, California, United States|33.78779,-117.85311

Key Eligibility Criteria

  • Female and male patients diagnosed with one of the following:
  • Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions
  • Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years
  • Non-breast cancer patients exposed to other anticancer therapies within the past 3 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →